Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GYRE logo GYRE
Upturn stock ratingUpturn stock rating
GYRE logo

Gyre Therapeutics Inc. (GYRE)

Upturn stock ratingUpturn stock rating
$8.28
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $19

1 Year Target Price $19

Analysts Price Target For last 52 week
$19 Target price
52w Low $6.11
Current$8.28
52w High $19

Analysis of Past Performance

Type Stock
Historic Profit -10.98%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 752.05M USD
Price to earnings Ratio 414
1Y Target Price 19
Price to earnings Ratio 414
1Y Target Price 19
Volume (30-day avg) 1
Beta -
52 Weeks Range 6.11 - 19.00
Updated Date 08/29/2025
52 Weeks Range 6.11 - 19.00
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.02

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-11
When -
Estimate 0.02
Actual 0.0022

Profitability

Profit Margin 4.08%
Operating Margin (TTM) 8.11%

Management Effectiveness

Return on Assets (TTM) 4.27%
Return on Equity (TTM) 7.84%

Valuation

Trailing PE 414
Forward PE 48.78
Enterprise Value 699073713
Price to Sales(TTM) 7.36
Enterprise Value 699073713
Price to Sales(TTM) 7.36
Enterprise Value to Revenue 6.84
Enterprise Value to EBITDA 60.99
Shares Outstanding 90826800
Shares Floating 20459640
Shares Outstanding 90826800
Shares Floating 20459640
Percent Insiders 87.16
Percent Institutions 3.78

ai summary icon Upturn AI SWOT

Gyre Therapeutics Inc.

stock logo

Company Overview

overview logo History and Background

Gyre Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for liver diseases. Founded in 2015, it has achieved milestones in preclinical and clinical development of its lead drug candidates. The company's evolution involves progressing therapies from research to late-stage clinical trials, seeking regulatory approvals, and establishing commercial partnerships.

business area logo Core Business Areas

  • Drug Development: Focuses on researching, developing, and testing novel therapies for liver diseases, including NASH and liver fibrosis.
  • Clinical Trials: Manages and conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
  • Commercialization: Involves the marketing and sales of approved therapies through partnerships or internal commercial teams.

leadership logo Leadership and Structure

The leadership team includes the CEO, CFO, CSO, and heads of clinical development and commercial operations. The organizational structure comprises research and development, clinical operations, regulatory affairs, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Firsocostat: An investigational ACC inhibitor for the treatment of Non-Alcoholic SteatoHepatitis (NASH) with liver fibrosis. Currently in clinical trials. Market share is currently 0% as the product is not yet commercialized. Competitors include Madrigal Pharmaceuticals (resmetirom).
  • Pyruvate Dehydrogenase Kinase (PDK) Inhibitors: A class of inhibitors for potential treatment of NASH. Currently in preclinical development. Market share is 0%. Competitors are emerging and are in early stages.

Market Dynamics

industry overview logo Industry Overview

The liver disease market is growing due to increasing prevalence of conditions like NASH, driven by obesity and diabetes. There is a high unmet need for effective therapies.

Positioning

Gyre Therapeutics Inc. is positioned as a player in the liver disease therapeutics market, focusing on NASH and liver fibrosis. Its competitive advantage lies in novel therapeutic targets and potential for improved efficacy.

Total Addressable Market (TAM)

The NASH market is projected to reach billions of dollars. Gyre is positioned to capture a share of the market once its drug candidates are approved and commercialized.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic targets
  • Strong preclinical and clinical data
  • Experienced management team
  • Potential for breakthrough therapies

Weaknesses

  • Limited financial resources
  • Reliance on clinical trial success
  • Competition from larger pharmaceutical companies
  • Uncertainty of regulatory approval

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new liver disease indications
  • Accelerated regulatory pathways
  • Growing prevalence of NASH and liver fibrosis

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from novel therapies
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • Madrigal Pharmaceuticals (MDGL)
  • Viking Therapeutics (VKTX)
  • Intercept Pharmaceuticals (ICPT)

Competitive Landscape

Gyre is in the competitive landscape with larger and more established pharmaceutical companies. It's focused on new therapies for liver disease, specifically NASH and Liver Fibrosis

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by advancing its drug candidates through preclinical and clinical development.

Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercial partnerships. Analyst estimates are not widely available.

Recent Initiatives: Recent initiatives include advancing firsocostat through Phase 2/3 clinical trials and expanding its pipeline of PDK inhibitors.

Summary

Gyre Therapeutics Inc. is a biopharmaceutical firm focusing on novel liver disease treatments, particularly NASH. It demonstrates potential with its innovative therapeutic targets and ongoing clinical trials. Its financial constraints and dependence on clinical success pose notable risks, highlighting the importance of strategic partnerships and effective execution. However, the increasing demand for effective liver disease therapies presents a significant market opportunity.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • ClinicalTrials.gov
  • SEC Filings
  • Industry Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered as financial advice. Market share estimates are approximate and may vary. The AI-based rating is subjective and should be used as one factor among many when evaluating investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Gyre Therapeutics Inc.

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2006-04-12
Interim CEO & Executive Chair Mr. Ping Zhang
Sector Healthcare
Industry Biotechnology
Full time employees 579
Full time employees 579

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.